ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Axonics, Inc. (AXNX) stock remained unchanged at -, trading at $70.98 on NASDAQ, unchanged from the previous close of -. The stock opened at -, fluctuating between $70.98 and $70.98 in the recent session.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Employees | 797 |
Beta | 0.83 |
Sales or Revenue | $366.38M |
5Y Sales Change% | 72.885% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep